Francois Brisebois
Stock Analyst at Oppenheimer
(1.73)
# 2,555
Out of 5,182 analysts
75
Total ratings
37.33%
Success rate
-0.72%
Average return
Main Sectors:
Stocks Rated by Francois Brisebois
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TRDA Entrada Therapeutics | Maintains: Outperform | $21 → $23 | $13.07 | +75.98% | 3 | Apr 6, 2026 | |
| TARS Tarsus Pharmaceuticals | Maintains: Outperform | $95 → $105 | $64.51 | +62.77% | 8 | Feb 25, 2026 | |
| AQST Aquestive Therapeutics | Maintains: Outperform | $7 → $8 | $4.34 | +84.33% | 3 | Sep 8, 2025 | |
| SVRA Savara | Maintains: Outperform | $5 → $6 | $5.28 | +13.64% | 6 | Aug 15, 2025 | |
| SNSE Sensei Biotherapeutics | Maintains: Outperform | $70 → $80 | $30.36 | +163.50% | 2 | Mar 28, 2025 | |
| ABEO Abeona Therapeutics | Initiates: Outperform | $16 | $5.38 | +197.40% | 1 | Mar 5, 2025 | |
| OVID Ovid Therapeutics | Upgrades: Outperform | $4 | $2.85 | +40.35% | 1 | Jan 29, 2025 | |
| HRMY Harmony Biosciences Holdings | Maintains: Outperform | $59 → $61 | $32.14 | +89.79% | 6 | Jan 13, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Outperform | $143 → $163 | $340.84 | -52.18% | 4 | Oct 31, 2024 | |
| DYN Dyne Therapeutics | Reiterates: Outperform | $55 | $19.21 | +186.31% | 5 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $0.19 | +8,003.73% | 2 | Aug 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $6 | $6.42 | -6.54% | 5 | Aug 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $4.21 | +161.28% | 6 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $14 | $39.49 | -64.55% | 2 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $55 → $65 | $15.31 | +324.56% | 5 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.68 | +495.24% | 2 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $36 | $16.60 | +116.87% | 4 | Aug 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $2,500 → $1,500 | $2.77 | +54,149.55% | 3 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $7,200 → $5,400 | $1.26 | +428,471.43% | 2 | Feb 6, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $17 → $11 | $2.12 | +418.87% | 2 | Aug 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $18 | $2.25 | +700.00% | 1 | Jul 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $50 | $9.25 | +440.54% | 1 | Oct 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $3,240 | $0.73 | +444,954.95% | 1 | Feb 4, 2020 |
Entrada Therapeutics
Apr 6, 2026
Maintains: Outperform
Price Target: $21 → $23
Current: $13.07
Upside: +75.98%
Tarsus Pharmaceuticals
Feb 25, 2026
Maintains: Outperform
Price Target: $95 → $105
Current: $64.51
Upside: +62.77%
Aquestive Therapeutics
Sep 8, 2025
Maintains: Outperform
Price Target: $7 → $8
Current: $4.34
Upside: +84.33%
Savara
Aug 15, 2025
Maintains: Outperform
Price Target: $5 → $6
Current: $5.28
Upside: +13.64%
Sensei Biotherapeutics
Mar 28, 2025
Maintains: Outperform
Price Target: $70 → $80
Current: $30.36
Upside: +163.50%
Abeona Therapeutics
Mar 5, 2025
Initiates: Outperform
Price Target: $16
Current: $5.38
Upside: +197.40%
Ovid Therapeutics
Jan 29, 2025
Upgrades: Outperform
Price Target: $4
Current: $2.85
Upside: +40.35%
Harmony Biosciences Holdings
Jan 13, 2025
Maintains: Outperform
Price Target: $59 → $61
Current: $32.14
Upside: +89.79%
Praxis Precision Medicines
Oct 31, 2024
Maintains: Outperform
Price Target: $143 → $163
Current: $340.84
Upside: -52.18%
Dyne Therapeutics
Sep 3, 2024
Reiterates: Outperform
Price Target: $55
Current: $19.21
Upside: +186.31%
Aug 19, 2024
Reiterates: Outperform
Price Target: $15
Current: $0.19
Upside: +8,003.73%
Aug 16, 2024
Reiterates: Outperform
Price Target: $6
Current: $6.42
Upside: -6.54%
Aug 15, 2024
Reiterates: Outperform
Price Target: $11
Current: $4.21
Upside: +161.28%
Aug 14, 2024
Reiterates: Outperform
Price Target: $14
Current: $39.49
Upside: -64.55%
Jun 13, 2024
Maintains: Outperform
Price Target: $55 → $65
Current: $15.31
Upside: +324.56%
May 6, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.68
Upside: +495.24%
Aug 17, 2023
Maintains: Outperform
Price Target: $63 → $36
Current: $16.60
Upside: +116.87%
Apr 3, 2023
Maintains: Outperform
Price Target: $2,500 → $1,500
Current: $2.77
Upside: +54,149.55%
Feb 6, 2023
Maintains: Outperform
Price Target: $7,200 → $5,400
Current: $1.26
Upside: +428,471.43%
Aug 29, 2022
Maintains: Outperform
Price Target: $17 → $11
Current: $2.12
Upside: +418.87%
Jul 18, 2022
Assumes: Outperform
Price Target: $18
Current: $2.25
Upside: +700.00%
Oct 29, 2021
Initiates: Outperform
Price Target: $50
Current: $9.25
Upside: +440.54%
Feb 4, 2020
Initiates: Buy
Price Target: $3,240
Current: $0.73
Upside: +444,954.95%